Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DaVita HealthCare Partner (NY: DVA )

135.90 -2.79 (-2.01%)
Streaming Delayed Price Updated: 1:55 PM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about DaVita HealthCare Partner

< Previous 1 2 3 4 5 6 Next >
Fresenius SE's Future With Dialysis Company Unclear, Investors Seek Answers
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite holding a 32% stake, challenges like high dialysis patient mortality and... 
Via Benzinga
6 Analysts Assess DaVita: What You Need To Know
Via Benzinga
Tandem Diabetes Catapults Above A Profit-Taking Zone, But DaVita Reverses, Nearly Triggering A Sell Signal
Tandem Diabetes stock surged above a profit-taking zone on Friday, but DaVita reversed course and tumbled at the open. 
Via Investor's Business Daily
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
Stock spinoffs can unlock shareholder value but management sometimes uses them to get rid of unwanted, slow-growing businesses. 
Via InvestorPlace
DaVita (DVA) Q1 2024 Earnings Call Transcript
DVA earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
DaVita Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Why DaVita Stock Popped Today
The dialysis services company handily beat expectations with its latest quarter. 
Via The Motley Fool
DaVita: Q4 Earnings Insights
Via Benzinga
DaVita Earnings Preview
Via Benzinga
DVA Stock Earnings: DaVita Beats EPS, Beats Revenue for Q1 2024
DVA stock results show that DaVita beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. 
Via InvestorPlace
Warren Buffett's 3 Best-Performing Stocks So Far in 2024: Are They Buys Now?
These high-flying Buffett stocks could be attractive to different kinds of investors. 
Via The Motley Fool
Ford, Nvidia Among Top S&P 500 Stocks Monday; Tesla Extends Losses
Ford, United Airlines and megacap AI stock Nvidia were big-cap winners. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily
The Best Warren Buffett Stocks to Buy With $300 Right Now
Even with $300, many Buffett investments are within reach of the average investor. 
Via The Motley Fool
3 Soaring, Highly-Ranked Value Stocks To Buy In April
The stock market bounced back on Wednesday and looked strong through morning trading Thursday until sellers showed up. 
Via Talk Markets
3 High-Dividend ETFs That Could Be Smart Investments Right Now
These are three great ways to get income in your portfolio without the hard work of choosing stocks and bonds on your own. 
Via The Motley Fool
Topics Bonds ETFs
Exposures Debt Markets
Warren Buffett's Berkshire Hathaway Owns Over 25% of These 4 Companies (Hint: Apple Isn't One of Them)
Berkshire even lists one of these companies as a subsidiary. 
Via The Motley Fool
3 No-Brainer Warren Buffett Stocks to Buy Right Now
Strong brands and market presence make these three companies attractive investments. 
Via The Motley Fool
Why Are Dialysis Provider Stocks Trading Higher On Tuesday?
Novo Nordisk's FLOW trial reveals a 24% reduction in kidney disease progression, cardiovascular events, and death with semaglutide 1.0 mg compared to placebo. Impact on dialysis stocks 
Via Benzinga
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance. 
Via Benzinga
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News
Novo Nordisk tested its diabetes and weight-loss drug in patients with chronic kidney disease. 
Via Investor's Business Daily
3 Cheap Stocks to Buy Now for Fast Gains
Dive into the world of investing with cheap stocks DaVita, Altria, and StoneCo as they show potential growth. 
Via InvestorPlace
Dialysis Player Fresenius Medical's Q4 Sales Hold Steady: Details
Fresenius Medical Care Q4 2023 revenue: €4.9 billion. Patient volume growth is expected at 0.5%-2% in 2024. 
Via Benzinga
3 Top-Rated Stocks To Buy After Comfortably Surpassing Earnings Expectations
This week’s earnings lineup has featured several top-rated stocks that have added to this optimistic growth narrative and here are a few to consider 
Via Talk Markets
Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
DaVita (DVA) Q4 2023 Earnings Call Transcript
DVA earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Time To Buy These High Growth Stocks As Earnings Approach
This week’s earnings lineup will be highlighted by several growth stocks with none standing out more than Airbnb and DaVita 
Via Talk Markets
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.